Like most on this board, I am stunned that with 2 drugs

New Post Public Reply Private Reply Replies (1) Message Board
petemantx
807
Like most on this board, I am stunned that with 2 drugs having the potential of Kevetrin and Brilacidin that we are still sitting in the shitter as to share price. I have utmost belief in the science, but I have absolutely no faith whatsoever in the bureaucratic BS of the Americn medical system, the clinical trial system, the involvement of the federal government in medical research, the FDA, CDC, and the AMA.

I believe Brilacidin did not fail the recent Covid trial but that the setup of the clinical trial (and IPIX mgt accepting the setup of the trial) as failing Brilacidin and the American public in bringing this drug to market. IMO the medical community is culpable for tens if not hundreds of thousands of deaths due to Covid worldwide. I base this on the mysteriously fast approval of very questionable vaccines, the stonewalling of new therapeutics and the handling of therapeutics in their entirety in regards to the Covid situation, the rigidity of the clinical trial program that causes undue delay in advancing promising treatments, the expected payola to many, many people in the whole medical bureaucratic system, and the lack of physicians demanding a change in the current monolithic system.

Do I sound pissed off? I hope so because I am irate over the whole situation.

Let's look at the history of Brilacidin to make my point. It was developed nearly 20 years ago (20 YEARS!!!!!!!), 2002, as that is when Polymedix was founded. Yet with all the history of research of its wonderful properties here we sit with no commercial applications for it yet. The government needs more testing of it even though the DeGrado Lab at UCSF has been researching defensin mimetics since 2013 and Brilacidin is considered the foundational drug of this new arm of medicine. Anybody else see a major problem here? It was shown to be superior to Daptomycin as a new age antibiotic that was pretty much immune to bacterial resistance and yet it has been shelved for many, many, many years due to lack of funds to run a phase 3 trial even though we keep hearing about the calamity of superbugs developing that can overcome all current antibiotics. I say the 3000 patient trial number the FDA is total BS and the lack of funds is a disgrace when the govt just gave Billions upon Billions to BPs to try and revamp their current load of outdated POS drugs to work against Covid. Typical government waste (or payobla) throwing money right down the crap hole. The invitro lab results of B against Covid were spectacular yet the trial was run at a far reduced dosage to that dosage IPIX wanted it run (at least that is what I have been led to believe). As to the trial, when they stopped it after 25% patients were enrolled to evaluate going from 3 to 5 days of dosings, they had to have seen the poor results to date but the committee of dolts didn't suggest upping the dosage in a possible new arm to see if that was the problem? No, they let it run out so that now to find if that was the problem a new trial would have to be run and thats another years delay, but hey, its only people still dying so what's the problem, right???

As for mgt, if the dosage was taken down by the FDA why didn't they also demand that the results be reduced drastically since they had to expect the results would be far less impressive than what the full dosage would have returned. Makes me wonder what the hell is Harkness doing as isn't she the trial person? After Prurisol and Brilacidin trials, I'd sack her ass in a heartbeat.

Bottom line - It seems quite evident that for IPIX to succeed and our drugs have any chance of seeing the light of day that we will be required to have a "favored" partner by the medical/government establishment. Another way of saying "greasing the right palms" IMO. If Leo hasn't figured this out yet maybe time to get rid of him. He has suffered nothing with his pay still quite robust (and has been all these last 10 years or so) and his "need for speed" is lacking IMO

No way in hell I believe it has taken this long for secondary/CU data to be collated as the data was locked in early Nov. I am hoping some major developments or even minor developments are revealed later this month but I am dreading all we hear is more time needed for further study and months to go before we hear of any grant money or some type of governmental money coming in.



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 193

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 75

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 208

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 15

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 142

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 108

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 79

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 195

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading

Top 5 Most Recently Viewed Articles

Enveric Biosciences Expands Patent Portfolio for Drug Development

Updated Category News Views 76

Enveric Biosciences Expands Patent Protection for EVM301 Portfolio Enveric Biosciences (NASDAQ: ENVB) is making remarkable strides in the biotechnology sector with its commitment to developing novel neuroplastogens aimed at treating neuropsychiatric disorders. This dedication has led to the expansion of its patent portfolio with the issuance of five new U.S. patents, as...

Continue Reading
DTCC Enhances Global Operations with New Hyderabad Office

Updated Category News Views 394

DTCC Expands Horizons with New Office in Hyderabad The Depository Trust & Clearing Corporation (DTCC), a key player in post-trade market infrastructures for the global financial services sector, recently celebrated the grand opening of its new office in Hyderabad, India. This expansion underscores the company’s strategic commitment to enhancing its capabilities in a...

Continue Reading
Overview of Ericsson's Annual General Meeting in 2025

Updated Category News Views 231

Ericsson's Annual General Meeting Highlights Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) held its Annual General Meeting (AGM) in Kista, focusing on significant corporate matters that impact shareholders and the company's strategic direction. This meeting provided an essential platform for stakeholders to participate in decision-making processes, even offering postal...

Continue Reading
Prospera Energy Inc. Optimizes Production with Recent Updates

Updated Category News Views 430

Prospera Energy Inc. Optimizes Production Strategies CALGARY, Alberta - Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) is making significant strides in enhancing its operational efficiency and expanding its energy production capabilities. In an exciting update, the Corporation has provided crucial insights into its recent service rig operations, successful acquisitions,...

Continue Reading
Exploring Growth in the Clean Label Ingredients Industry

Updated Category News Views 287

The Clean Label Ingredients Market: A New Era of Transparency The global clean label ingredients market is flourishing as consumers increasingly seek natural food products. With the demand for preservative-free and organic food additives on the rise, the food industry is shifting dramatically. This transformation centers on enhancing transparency in food labeling and...

Continue Reading